Targeting the hypoxic conditions and HIF1α function in combination with anti-PD-L1 immunotherapy can overpass the adverse effect PD-L1, whether attributed to HIF1α or IFNγ in the TME, by enhancing the recognition of cancer cells and allowing effective cancer cell killing by the immune system. This evidence concerns the gene HIF1A and cancer.